S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:HALO

Halozyme Therapeutics Stock Forecast, Price & News

$49.50
+2.00 (+4.21 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$46.68
Now: $49.50
$49.55
50-Day Range
$39.23
MA: $43.13
$48.27
52-Week Range
$12.71
Now: $49.50
$49.55
Volume947,315 shs
Average Volume1.29 million shs
Market Capitalization$6.69 billion
P/E Ratio309.38
Dividend YieldN/A
Beta1.77
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics logo

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

392nd out of 1,925 stocks

Biological Products, Except Diagnostic Industry

50th out of 177 stocks

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889
Employees132

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$195.99 million
Book Value$0.63 per share

Profitability

Net Income$-72,240,000.00

Miscellaneous

Market Cap$6.69 billion
Next Earnings Date2/22/2021 (Estimated)
OptionableOptionable
$49.50
+2.00 (+4.21 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

How has Halozyme Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HALO stock has increased by 171.7% and is now trading at $49.50.
View which stocks have been most impacted by COVID-19
.

Is Halozyme Therapeutics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Halozyme Therapeutics?

Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Halozyme Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Halozyme Therapeutics' CEO?

1,448 employees have rated Halozyme Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Halozyme Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Halozyme Therapeutics
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Monday, November, 2nd. The biopharmaceutical company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.20 by $0.05. The biopharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $59.35 million. Halozyme Therapeutics had a net margin of 10.78% and a return on equity of 24.29%. The company's revenue was up 41.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.17) EPS.
View Halozyme Therapeutics' earnings history
.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2021 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of 1.40-1.55 for the period, compared to the Thomson Reuters consensus estimate of $1.79. The company issued revenue guidance of $375-395 million, compared to the consensus revenue estimate of $403.71 million.

What price target have analysts set for HALO?

11 brokerages have issued 12 month price objectives for Halozyme Therapeutics' shares. Their forecasts range from $20.00 to $60.00. On average, they expect Halozyme Therapeutics' stock price to reach $39.46 in the next year. This suggests that the stock has a possible downside of 20.3%.
View analysts' price targets for Halozyme Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Halozyme Therapeutics' key competitors?

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil Co. (ATH.TO) (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 58, Pay $1.49M)
  • Ms. Elaine D. Sun, Sr. VP & CFO (Age 49)
  • Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 57)
  • Mr. Ed Gemo, VP, Chief Information & Security Officer
  • Mr. Albert S. Kildani, VP of Investor Relations & Corp. Communications
  • Mr. Masaru Matsuda Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50)
  • Ms. Amy Marinne Fox, VP of HR
  • Mr. William J. Fallon, Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances (Age 64)
  • Dr. Steve Knowles, Chief Medical Officer
  • Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.54%), Scout Investments Inc. (0.22%), AMI Asset Management Corp (0.18%), Louisiana State Employees Retirement System (0.02%), TIAA FSB (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics
.

Which institutional investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., AMI Asset Management Corp, Cutler Group LP, Sawgrass Asset Management LLC, TIAA FSB, Bellecapital International Ltd., and Sowell Financial Services LLC. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Halozyme Therapeutics stock?

HALO stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, State of Alaska Department of Revenue, Crossmark Global Holdings Inc., Hexavest Inc., Joel Isaacson & Co. LLC, Scout Investments Inc., Pacer Advisors Inc., and Sheets Smith Wealth Management.
View insider buying and selling activity for Halozyme Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $49.50.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $6.69 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 132 workers across the globe.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.